JNJ Johnson & Johnson

159.2
-1.04  -1%
Previous Close 160.24
Open 160.6
52 Week Low 142.86
52 Week High 179.92
Market Cap $419,109,437,465
Shares 2,632,596,969
Float 2,630,990,400
Enterprise Value $424,774,338,312
Volume 8,523,072
Av. Daily Volume 6,816,897
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
HVTN 706/HPX3002 (Mosaico)
HIV in MSM and Transgender
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
JNJ-75220795
Non-alcoholic steatohepatitis (NASH)
Phase 1
Phase 1
Phase 1 trial ongoing.
JNJ-78436735 (Ad26.COV2-S) - (ENSEMBLE-2)
COVID-19 vaccine - two-dose regimen
Phase 3
Phase 3
Phase 3 data showed 100 percent protection against severe/critical COVID-19 – at least 14 days post-final vaccination. 75 percent protection against symptomatic (moderate to severe/critical) COVID-19 globally. 94 percent protection against symptomatic COVID-19 in the U.S, September 21, 2021. An additional Phase 1/2a data showing that when a booster of the vaccine was given 6 months after the single shot, antibody levels increased nine-fold 1 week after the booster and continued to climb to 12-fold higher 4 weeks after the booster. EUA amendment submitted to FDA - October 5, 2021. EUA for second dose for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine, noted October 20, 2021.
ZYTIGA (abiraterone acetate) - (PEACE1)
Prostate Cancer
Phase 3
Phase 3
Phase 3 data showed OS was improved by abiraterone both in the overall population (HR: 0.83; medians: 5.7 vs 4.7 yrs) and in the ADT+ docetaxel population (HR: 0.75; medians: NR vs 4.4 yrs), noted September 16, 2021.
JNJ-78436735 (Ad26.COV2-S) - (ENSEMBLE)
COVID-19 vaccine (single dose)
Approved
Approved
Approval by FDA announced February 27, 2021. Phase 3 data showed 75 percent overall efficacy against severe/critical COVID-19, across all ages and countries. 74 percent efficacy in the U.S. against severe/critical COVID-19; 89 percent against hospitalization; 83 percent against COVID-19-related death, September 21, 2021.
HVTN 705/HPX2008 (Imbokodo)
HIV in Women
Phase 2b
Phase 2b
Phase 2b data did not meet endpoints, study will not continue - August 31, 2021.
DARZALEX (Daratumumab) in combination with Pomalyst (pomalidomide) and dexamethasone
Multiple myeloma
Approved
Approved
FDA approval announced July 12, 2021.
DARZALEX (Daratumumab)
Newly Diagnosed Multiple Myeloma (NDMM)
Approved
Approved
FDA Approval announced June 28, 2019.
BALVERSA (erdafitinib)
Urothelial cancer
Approved
Approved
FDA Approval announced April 12, 2019.
DARZALEX (Daratumumab) + bortezomib, thalidomide and dexamethasone (VTd)
Multiple myeloma - candidates for autologous stem cell transplant (ASCT)
Approved
Approved
FDA Approval announced September 26, 2019.
SPRAVATO (esketamine)
Major depressive disorder (MDD)
Approved
Approved
FDA approval announced August 3, 2020.
SPRAVATO (esketamine)
Treatment resistant depression
Approved
Approved
FDA approval announced March 5, 2019.
ERLEADA (apalutamide)
Metastatic castration-sensitive prostate cancer (mCSPC).
Approved
Approved
FDA Approval announced September 18, 2019.
ERLEADA (apalutamide)
Non-metastatic castration-resistant prostate cancer (CRPC)
Approved
Approved
Approval announced February 14, 2018.
INVOKANA (canagliflozin)
Diabetic Kidney Disease
Approved
Approved
FDA Approval announced September 30, 2019.
INVOKANA (canagliflozin)
Type 2 diabetes
Approved
Approved
FDA Approval announced October 30, 2018.
Generic COPAXONE
Multiple sclerosis
Approved
Approved
Filed 2007. Approved April 16 2015.
DARZALEX (Daratumumab) and KYPROLIS (carfilzomib)
Multiple Myeloma
Approved
Approved
FDA approval announced August 20, 2020.
DARZALEX (Daratumumab)
Frontline multiple myeloma (non-transplant)
Approved
Approved
Approval announced May 7, 2018.
TREMFYA (Guselkumab) - (GALAXI 1)
Crohn's disease
Phase 2/3
Phase 2/3
Phase 2/3 trial initiation announced July 11, 2018.
TREMFYA (Guselkumab)
Plaque psoriasis
Approved
Approved
Approval announced February 27, 2019.
TREMFYA (Guselkumab)
Ulcerative colitis
Phase 2
Phase 2
Phase 2a initiation announced January 17, 2019.
TREMFYA (Guselkumab)
Psoriatic Arthritis
Approved
Approved
FDA Approval announced July 14, 2020.
TREMFYA (Guselkumab)
Plaque psoriasis
Approved
Approved
Approval announced July 13, 2017.
IMBRUVICA (Ibrutinib)
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approved
Approval announced August 2, 2017.
IMBRUVICA (Ibrutinib)
Marginal zone lymphoma
Approved
Approved
Approved January 19, 2017.
IMBRUVICA (ibrutinib) and RITUXAN (rituximab)
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
Approved
FDA Approval announced April 21, 2020.
Nipocalimab (M281)
generalized myasthenia gravis (gMG)
Phase 2
Phase 2
Phase 2 trial met primary endpoint - June 15, 2020. Phase 3 trial to be initiated 1Q 2021.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Approved
Approved
FDA approval announced January 15, 2021.
Amivantamab
Non-small cell lung cancer (NSCLC)
BLA Filing
BLA Filing
BLA filing announced December 3, 2020.
Paliperidone
Schizophrenia
sNDA Filing
sNDA Filing
sNDA filing announced November 2, 2020.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma
Approved
Approved
FDA Approval announced May 1, 2020.
Ponesimod
Relapsing multiple sclerosis
NDA Filing
NDA Filing
NDA filing announced March 18, 2020.
STELARA (USTEKINUMAB)
Ulcerative colitis
Approved
Approved
FDA Approval announced October 21, 2019.
XARELTO (rivaroxaban)
Reduce the Risk of Recurrent Venous Thromboembolism (VTE)
Approved
Approved
FDA approval announced October 14, 2019.
DARZALEX (Daratumumab) + pomalidomide and dexamethasone
Relapsed or refractory multiple myeloma
Approved
Approved
Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
Approved
FDA approval announced August 27, 2018.
D/C/F/TAF
HIV
Approved
Approved
FDA Approval announced July 17, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Atabecestat
Alzheimer’s disease
Phase 2
Phase 2
Announced May 18, 2018 that dosing will be stopped.
ZYTIGA (abiraterone acetate) - LATITUDE
metastatic hormone-naïve prostate cancer (mHNPC)
Approved
Approved
sNDA approval announced February 8, 2018.
STELARA (USTEKINUMAB)
Plaque psoriasis
Approved
Approved
Approval announced October 13, 2017.
SIMPONI ARIA
Psoriatic arthritis (PsA)
Approved
Approved
Approval announced October 20, 2017.
Sirukumab
Rheumatoid arthritis
CRL
CRL
CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.
SIMPONI ARIA
Ankylosing Spondylitis
Approved
Approved
Approval announced October 20, 2017.
XARELTO (rivaroxaban)
Coronary Artery Disease or Peripheral Artery Disease
Phase 3
Phase 3
Phase 3 trial stopped early due to positive efficacy - February 8, 2017.
Talacotuzumab
Acute myeloid leukemia (AML)
Phase 3
Phase 3
Phase 3 discontinuation announced October 17, 2017.

Latest News

  1. NEW BRUNSWICK, N.J., Nov. 12, 2021 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE:JNJ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company. The planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.

    Following the planned separation, the new Johnson & Johnson would remain the world's largest and most diverse healthcare company and continue its commitment to lead in global healthcare R&D and innovation, with a portfolio that blends its strong Pharmaceutical and Medical Device capabilities focused on advancing…

    NEW BRUNSWICK, N.J., Nov. 12, 2021 /PRNewswire/ -- Johnson & Johnson (the "Company") (NYSE:JNJ) today announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company. The planned separation would create two global leaders that are better positioned to deliver improved health outcomes for patients and consumers through innovation, pursue more targeted business strategies and accelerate growth.

    Following the planned separation, the new Johnson & Johnson would remain the world's largest and most diverse healthcare company and continue its commitment to lead in global healthcare R&D and innovation, with a portfolio that blends its strong Pharmaceutical and Medical Device capabilities focused on advancing the standard of care through innovation and technology. As previously announced, Mr. Alex Gorsky will serve as Executive Chairman of Johnson & Johnson and transition the Chief Executive Officer role to Mr. Joaquin Duato, currently Vice Chairman of the Company's Executive Committee, effective January 3, 2022. Mr. Duato would continue to lead the new Johnson & Johnson following completion of the planned separation.

    The New Consumer Health Company would be a leading global consumer health company, touching the lives of over one billion consumers around the world every day through iconic brands such as Neutrogena, AVEENO®, Tylenol®, Listerine®, JOHNSON's®, and BAND-AID® and continuing its legacy of innovation. The New Consumer Health Company's Board of Directors and executive leadership would be determined and announced in due course as the planned separation process progresses.

    Mr. Gorsky said, "Throughout our storied history, Johnson & Johnson has demonstrated that we can deliver results that benefit all our stakeholders, and we must continually be evolving our business to provide value today, tomorrow and in the decades ahead. Following a comprehensive review, the Board and management team believe that the planned separation of the Consumer Health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and – most importantly – improve healthcare outcomes for people around the world." 

    Mr. Gorsky continued, "For the new Johnson & Johnson, this planned separation underscores our focus on delivering industry-leading biopharmaceutical and medical device innovation and technology with the goal of bringing new solutions to market for patients and healthcare systems, while creating sustainable value for shareholders. We believe that the New Consumer Health Company would be a global leader across attractive and growing consumer health categories, and a streamlined and targeted corporate structure would provide it with the agility and flexibility to grow its iconic portfolio of brands and innovate new products. We are committed to the success of each organization, as well as our company's more than 136,000 employees around the globe, who will remain the backbone of these businesses." 

    Mr. Duato commented, "This planned transaction would create two businesses that are each financially strong and leaders in their respective industries. We believe that the new Johnson & Johnson and the New Consumer Health Company would each be able to more effectively allocate resources to deliver for patients and consumers, drive growth and unlock significant value. Importantly, the new Johnson & Johnson and the New Consumer Health Company would remain mission driven companies with exceptional brands, commitments to innovation, and remarkable talent. Each company would carry on the Johnson & Johnson legacy of putting the needs and well-being of the people we serve first."

    The planned separation is expected to create value for all stakeholders by aiming to achieve the following key goals: 

    • Increase management focus, resources, agility and speed to effectively address differing industry trends and to better meet the needs of the new Johnson & Johnson and the New Consumer Health Company patients and consumers;
    • Further focus capital allocation based on the objectives of each independent company;
    • Provide each company with a compelling financial profile that more accurately reflects the strengths and opportunities of each business and, as a result, offers investors a more targeted investment opportunity; and
    • Align corporate and operational structures so each company is better able to drive growth and value creation.

    New Johnson & Johnson: An Innovative Pharmaceuticals and Medical Devices Leader with Sharpened Focus on Major Unmet Medical Needs and Advancing Standard of Care for Patients Around the World

    Following the planned separation, the new Johnson & Johnson would remain the world's largest and most diverse healthcare company and maintain a portfolio that blends its strong Pharmaceutical and Medical Device capabilities focused on materially advancing the standard of care through biopharmaceutical and medical device innovation and technology. Leveraging its long-standing strength in core areas of science, technology, regulatory, supply chain and global commercial reach, the new Johnson & Johnson would continue to build on its offering of life-saving treatments, including DARZALEX, ERLEADA, IMBRUVICA, STELARA and TREMFYA, as well as medical device solutions across interventional solutions, orthopaedics, surgery and vision.

    The new Johnson & Johnson would remain committed to changing the trajectory of human health. The Pharmaceutical and Medical Devices segments, which are expected to generate revenue of approximately $77 billion in Full-Year 20211, are united by their shared and complementary focus on scientific research and development to serve similar end users – patients and healthcare providers – and operate in similar regulatory and competitive environments. The new Johnson & Johnson is expected to be better positioned to combine skills, expertise and approaches to bring integrated, comprehensive and more impactful care to patients, addressing diseases in areas such as oncology and eye health that require a combination of surgical, interventional and pharmaceutical treatments. The new Johnson & Johnson would continue to play a leading role in advancing the industry forward by creating novel solutions, bringing together treatments spanning therapeutics, robotics, artificial intelligence and more, to change the way diseases are prevented, intercepted and eventually cured.

    The Pharmaceutical business would continue to generate sustained above market growth by advancing its strong portfolio and pipeline of products, accelerating key therapeutic areas, such as oncology and immunology, while also advancing new therapeutic modalities such as cell and gene therapies. At the same time, the Medical Devices business would plan to accelerate its momentum across orthopaedics, interventional solutions, surgery and vision, with an increased cadence of meaningful innovation enabled by a strong digital surgery pipeline and focus on execution across all geographies.

    The new Johnson & Johnson would remain committed to maintaining a strong balance sheet and to its stated capital allocation priorities of R&D investment, competitive dividends and value-creating acquisitions.

    New Consumer Health Company Post-Separation: A Leading Global Consumer Health Company with Iconic Brands and Commitment to Continued Innovation

    The New Consumer Health Company would be a global leader with a powerful portfolio of iconic brands — comprising four $1 billion megabrands and 20 brands over $150 million — and leading positions in Self Care (OTC), Skin Health and Essential Health, which includes baby care, feminine care, wound care and oral health. The Consumer Health segment is expected to generate revenue of approximately $15 billion in Full-Year 20212 and, following the planned separation, the New Consumer Health Company would generate sales in over 100 countries, driven by world-class innovation capabilities and demonstrated business momentum. 

    In recent years, Johnson & Johnson has focused the Consumer Health business and advanced its innovation, enabling it to reach more consumers with products that truly make a difference in peoples' lives, while simultaneously expanding margins and delivering healthy financial results. These actions have bolstered positions in Self Care, Skin Health and Essential Health.

    The New Consumer Health Company would be expected to benefit from a strong investment grade profile and balance sheet that would allow it to build on its long history of innovation and maintain and extend its leadership position across important and growing categories.

    The planned organizational design for the New Consumer Health Company is expected to be completed by the end of 2022 and will be subject to legal requirements including consultation with works councils and employee representatives, as required. Planned New Consumer Health Company employees are expected to continue participating in their current Johnson & Johnson pay, benefits and retirement programs through the end of 2022.

    Transaction Details

    The Board of Directors' intent is to effect the planned separation through the capital markets, creating two independent, market-leading companies. The transaction is intended to qualify as a tax-free separation for U.S. federal income tax purposes.

    In addition, it is expected that the overall shareholder dividend will remain at least at the same level following the completion of the transaction.

    The Company is targeting completion of the planned separation in 18 to 24 months, subject to the satisfaction of certain conditions including, among others, consultations with works councils and other employee representative bodies, as required, final approval of Johnson & Johnson's Board of Directors, receipt of a favorable opinion and Internal Revenue Service ruling with respect to the tax-free nature of the transaction, and the receipt of other regulatory approvals. There can be no assurance regarding the ultimate timing of the proposed transaction or that the transaction will be completed.

    Advisors

    Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as financial advisors to Johnson & Johnson, and Cravath, Swaine & Moore LLP and Baker & McKenzie LLP are acting as legal counsel.

    Investor Conference Call

    The Company plans to hold an investor webcast to discuss this announcement and provide opportunity for Q&A today at 8:30 a.m. ET. The call will be hosted by Mr. Joseph Wolk, Chief Financial Officer, Mr. Alex Gorsky, Chairman and CEO, and Mr. Joaquin Duato, Vice Chairman of the Executive Committee. The webcast is accessible at www.investor.jnj.com and telephone, for both "listen-only" participants and financial analysts who wish to take part in the question and answer portion of the call. Please dial (877) 869-3847 in the U.S. and (201) 689-8261 outside of the U.S. 

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

    Cautions Concerning Forward-Looking Statements

    This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: the anticipated separation of Johnson & Johnson's Consumer Health business; future operating and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: Johnson & Johnson's ability to satisfy the necessary conditions to consummate the separation of Johnson & Johnson's Consumer Health business on a timely basis or at all, Johnson & Johnson's ability to successfully separate Johnson & Johnson's Consumer Health business and realize the anticipated benefits from the separation, the New Consumer Health Company's ability to succeed as a standalone publicly traded company, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including unexpected clinical trial results, additional analysis of existing clinical data, uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; the impact of business combinations and divestitures; challenges to patents; the impact of patent expirations; the ability of Johnson & Johnson to successfully execute strategic plans, including restructuring plans; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws, global health care reforms and import/export and trade laws; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in Johnson & Johnson's most recently filed Quarterly Report on Form 10-Q and in Johnson & Johnson's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

    1 Figures represent Total Reported Sales from the 2021 Midpoint of October Sales Dollar Guidance excluding Vaccine. Sales dollars are allocated to segments based on September 2021 YTD Actuals sales mix. 

    2 Figures represent Total Reported Sales from the 2021 Midpoint of October Sales Dollar Guidance excluding Vaccine. Sales dollars are allocated to segments based on September 2021 YTD Actuals sales mix.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-announces-plans-to-accelerate-innovation-serve-patients-and-consumers-and-unlock-value-through-intent-to-separate-consumer-health-business-301422942.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  2. NEW BRUNSWICK, N.J., Nov. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people. The first deliveries to the COVAX Humanitarian Buffer are anticipated to begin in the coming days.

    The COVAX Humanitarian Buffer is part of the COVAX Facility and is designed to ensure that people in conflict zones or humanitarian settings can access COVID-19 vaccines, even if they live beyond the reach of traditional, government vaccination campaigns. Governments and national and international…

    NEW BRUNSWICK, N.J., Nov. 10, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) (the Company) has entered into an agreement with the U.S. Government and Gavi, the Vaccine Alliance (Gavi), to enable access to its single-shot COVID-19 vaccine through a novel mechanism – the COVAX Humanitarian Buffer – that will serve to protect the world's most vulnerable people. The first deliveries to the COVAX Humanitarian Buffer are anticipated to begin in the coming days.

    The COVAX Humanitarian Buffer is part of the COVAX Facility and is designed to ensure that people in conflict zones or humanitarian settings can access COVID-19 vaccines, even if they live beyond the reach of traditional, government vaccination campaigns. Governments and national and international humanitarian agencies are eligible to apply to receive doses from the COVAX Humanitarian Buffer. If applications are granted and the doses allocated, the governments or humanitarian agencies that filed the application then carry out the vaccination campaigns to ensure people are protected from COVID-19.

    "We believe our single-shot COVID-19 vaccine has a critical role to play in conflict zones and other humanitarian settings that can't be reached by government vaccination campaigns, and we are proud to be part of this effort to protect the world's most vulnerable people," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer. "From the beginning of the pandemic, Johnson & Johnson has recognized that no one is safe until everyone is safe and has worked to develop and deliver a vaccine that can protect the health of people everywhere."

    The establishment of the COVAX Humanitarian Buffer is of critical importance to global health and ending the COVID-19 pandemic for everyone, everywhere. The Inter-Agency Standing Committee, the longest-standing and highest-level humanitarian coordination forum of the United Nations system, estimates that approximately 167 million people, including an estimated 60-80 million people in areas beyond the reach of national health authorities, are at risk of exclusion from COVID-19 vaccination. Vaccinating these people, who represent some of the world's most vulnerable populations, is crucial given that many of them may lack access to other healthcare resources should they be sickened by COVID-19.

    Equitable Global Access to the Johnson & Johnson COVID-19 Vaccine

    Johnson & Johnson is committed to facilitating equitable global access to its COVID-19 vaccine, and believes it is critical to protect as many people as possible against hospitalization and death. The Company has committed to providing its vaccine on a not-for-profit basis globally for emergency pandemic use, and is making available up to 900 million doses of its vaccine to the COVAX Facility and the African Union through 2022.

    The Company firmly believes that inequitable access to COVID-19 vaccines will only prolong the pandemic, and is strongly advocating that governments with available doses follow the example of the U.S., the U.K. and other countries, and immediately ramp up dose sharing, particularly through the COVAX Facility. 

    About the Johnson & Johnson COVID-19 Vaccine

    The Johnson & Johnson COVID-19 vaccine was developed and is being manufactured using Janssen's proprietary AdVac® viral vector technology. The AdVac® vaccine platform is also used for the Company's Ebola vaccine regimen, and its candidates for preventing respiratory syncytial virus (RSV) and HIV.

    The profile of the COVID-19 vaccine enables delivery to remote areas. The vaccine is estimated to remain stable for two years at -20 °C (-4 °F). It can be kept at temperatures of 2-8 °C (36-46 °F) for a maximum of six months of that two-year period, based on local labelling requirements. This enables the vaccine to be shipped using the same cold chain technologies used to transport other medicines and vaccines in routine use.

    The Johnson & Johnson single-shot COVID-19 vaccine received an Emergency Use Authorization (EUA) in the United States on February 27, 2021, and on October 20, 2021, the FDA authorized for emergency use a booster shot of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with the Company's single-shot vaccine.

    In addition, the European Commission granted Conditional Marketing Authorization (CMA) on March 11, 2021, the WHO issued Emergency Use Listing on March 12, and the Company received an interim recommendation from the Strategic Advisory Group of Experts (SAGE) on Immunization for the WHO on March 17. Many more authorizations have been granted in countries worldwide, and regulatory submissions are ongoing.

    For more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.

    About the Janssen Pharmaceutical Companies of Johnson & Johnson

    At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology and Pulmonary Hypertension.

    Learn more at www.janssen.com. Follow us at @JanssenUS and @JanssenGlobal. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

    About Johnson & Johnson 

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews

    Cautions Concerning Forward-Looking Statements 

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. 

    1 Inter-Agency Standing Committee. Frequently Asked Questions: The COVAX Humanitarian Buffer. 8 November 2021. Available at: https://interagencystandingcommittee.org/system/files/2021-11/Frequently Asked Questions- The COVAX Humanitarian Buffer%2C 8 November 2021.pdf. Accessed 9 November 2021.

    (PRNewsfoto/Johnson & Johnson)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-enters-into-agreement-to-provide-its-single-shot-covid-19-vaccine-for-the-worlds-most-vulnerable-people-through-novel-humanitarian-buffer-301421681.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  3. NEW BRUNSWICK, N.J., Nov. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health. This new category of awards will be presented annually as part of the Research!America Advocacy Awards Program, now in its 26th year. Johnson & Johnson is a founding member of the Research!America alliance, which launched in 1989.  This year's winners include leaders who are addressing some of the biggest health challenges of our time, from smoking cessation to diversity in clinical trials to fueling collaboration to advance solutions for COVID-19.

    "As part of the global…

    NEW BRUNSWICK, N.J., Nov. 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that it has provided a $5MM endowment to Research!America to create an annual award to recognize individuals and organizations working to make a profound difference in public health. This new category of awards will be presented annually as part of the Research!America Advocacy Awards Program, now in its 26th year. Johnson & Johnson is a founding member of the Research!America alliance, which launched in 1989.  This year's winners include leaders who are addressing some of the biggest health challenges of our time, from smoking cessation to diversity in clinical trials to fueling collaboration to advance solutions for COVID-19.

    "As part of the global public health community, Johnson & Johnson is delighted to collaborate with Research!America to honor the public health heroes whose energy and commitment have made a profound difference in advancing the health of entire populations," said William Hait, M.D., Ph.D., Global Head, Johnson & Johnson External Innovation. "Their work impacts all of us, and we are proud to celebrate their valuable contributions through endowing this Award."

    While medicine is often focused on disease treatment, public health focuses on prevention of disease and injuries, and promoting safety and wellness through research, education and policy making.

    "We are deeply appreciative of Johnson & Johnson's generous endowment focused on raising the profile of public health and its numerous heroes as they fight day in and day out to advance the public good," said Mary Woolley, president and CEO of Research!America. "For more than 30 years, Johnson & Johnson has been a highly valued strategic partner, contributing expertise, vision, and unwavering resolve to our goal of improving and saving lives through medical and public health research."

    Johnson & Johnson has invited the honorees to share their stories as part of EUREKA MOMENTS, a series that chronicles the journeys of the people behind the breakthroughs that are improving the lives of millions around the world.  The series will air on the company's YouTube channel on Tuesdays at noon EST

    "The individuals and organizations honored with the inaugural Research!America Outstanding Achievement in Public Health Awards exemplify the vision, passion, and commitment that it takes to make a profound impact on the health and well-being of communities around the world," said Seema Kumar, Global Head, Office of Innovation, Global Health and Scientific Engagement, Johnson & Johnson. "We look forward to sharing the remarkable stories of how these public health champions have persevered against all odds and against seemingly impossible problems through the EUREKA MOMENTS series."

    Learn more about this year's honorees:

    • Three honorees will receive the Outstanding Achievement in Public Health Award, which recognizes individuals for their extraordinary work and enormous contributions to public health.
      • Matthew Myers, president, Campaign for Tobacco-Free Kids, and Bill Novelli, founder and chair, Campaign for Tobacco-Free Kids, professor and founder, Business for Impact, McDonough School of Business, Georgetown University. Myers and Novelli are longtime leaders in the fight to reduce tobacco use and its deadly consequences. Their advocacy efforts have led to drastic decreases in both youth and adult smoking on a global scale since the Campaign for Tobacco-Free Kids was founded in 1996.
      • Vivian W. Pinn, MD, inaugural director, NIH Office of Research on Women's Health (retired). Dr. Pinn's many contributions to public health include her leadership in assuring greater inclusion of women and minorities in clinical trials and promoting the consideration of sex differences in the formulation and execution of research studies.
    • Christopher Murray, MD, DPhil, professor and chair of health metrics sciences and director, Institute for Health Metrics and Evaluation, University of Washington School of Medicine is the recipient of the Building the Foundation Award, which recognizes one or more individuals whose basic research discoveries have played a pivotal role in advancing public health. Dr. Murray created the first COVID-19 global forecast that decision makers have used as a roadmap for ending the pandemic, and  state-level forecasts that have been essential to on-the-ground response efforts.
    • Ashish K. Jha, MD, MPH, dean, Brown University School of Public Health, is the recipient of the Meeting the Moment for Public Health Award, which recognizes an individual or organization that has been a "clear voice," playing a key role in communicating public health information and developments to members of the public. Dr. Jha's masterful ability and tireless commitment to conveying key information about COVID-19 to a wide array of audiences has helped keep the public informed and combat mis- and disinformation.
    • Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is the recipient of the Rapid Translation Award, which recognizes a public-private partnership that has made a critical contribution to public health progress. ACTIV made crucial contributions to the rapid-pace development of COVID-19 treatments and vaccines by designing master protocols, establishing national standards, and identifying best practices and collaboration opportunities to improve every stage of the prevention and treatment R&D pipeline.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.

    (PRNewsfoto/Johnson & Johnson)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-endows-researchamerica-outstanding-achievement-in-public-health-awards-301420352.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  4. NEW BRUNSWICK, N.J., Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE:JNJ) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine.

    "Today's recommendation supports the use of the Johnson & Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. "The Johnson & Johnson vaccine provided 94 percent protection in the U.S. against COVID-19 when given…

    NEW BRUNSWICK, N.J., Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (the Company) (NYSE:JNJ) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine.

    "Today's recommendation supports the use of the Johnson & Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive," said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson. "The Johnson & Johnson vaccine provided 94 percent protection in the U.S. against COVID-19 when given as a booster following the single-shot Johnson & Johnson vaccine, and due to its unique mechanism of action, offers long-lasting, durable protection. We remain confident in the benefit it will provide to millions around the world."

    The Johnson & Johnson COVID-19 vaccine was recommended as a booster for adults aged 18 and older who received the Johnson & Johnson single-shot vaccine at least two months earlier. A booster dose of the Johnson & Johnson COVID-19 vaccine was also recommended for eligible adults at least six months following the second dose of an authorized mRNA vaccine.

    The ACIP recommendation has been forwarded to the Director of the CDC and the U.S. Department of Health and Human Services (HHS) for review and adoption.

    The Company's single-dose COVID-19 vaccine received FDA Emergency Use Authorization  for adults aged 18 and older on February 27, 2021. On October 20, 2021, the FDA authorized for emergency use a booster shot of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with the Company's single-dose vaccine.

    For more information on the Company's multi-pronged approach to helping combat the pandemic, visit: www.jnj.com/covid-19.

    Authorized Use

    The Janssen COVID-19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to provide:

    • Primary vaccination regimen for the Janssen COVID-19 Vaccine is a single-dose (0.5 mL) administered to individuals 18 years of age and older.
    • A single Janssen COVID-19 Vaccine booster dose (0.5 mL) may be administered at least 2 months after the primary vaccination to individuals 18 years of age and older.
    • A single booster dose of the Janssen COVID-19 Vaccine (0.5 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID-19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination.

    IMPORTANT SAFETY INFORMATION

    WHAT SHOULD YOU MENTION TO YOUR VACCINATION PROVIDER BEFORE YOU GET THE JANSSEN COVID-19 VACCINE?

    Tell the vaccination provider about all of your medical conditions, including if you:

    • have any allergies
    • have a fever
    • have a bleeding disorder or are on a blood thinner
    • are immunocompromised or are on a medicine that affects your immune system
    • are pregnant or plan to become pregnant
    • are breastfeeding
    • have received another COVID-19 vaccine
    • have ever fainted in association with an injection

    WHO SHOULD NOT GET THE JANSSEN COVID-19 VACCINE?

    You should not get the Janssen COVID-19 Vaccine if you:

    • had a severe allergic reaction after a previous dose of this vaccine
    • had a severe allergic reaction to any ingredient of this vaccine.

    HOW IS THE JANSSEN COVID-19 VACCINE GIVEN?

    The Janssen COVID-19 Vaccine will be given to you as an injection into the muscle. 

    Primary Vaccination: The Janssen COVID-19 Vaccine is administered as a single dose.

    Booster Dose:

    • A single booster dose of the Janssen COVID-19 Vaccine may be administered at least two months after primary vaccination with the Janssen COVID-19 Vaccine.
    • A single booster dose of the Janssen COVID-19 Vaccine may be administered to eligible individuals who have completed primary vaccination with a different authorized or approved COVID-19 vaccine. Please check with your health care provider regarding eligibility for and timing of the booster dose.

    WHAT ARE THE RISKS OF THE JANSSEN COVID-19 VACCINE?

    Side effects that have been reported with the Janssen COVID-19 Vaccine include:

    • Injection site reactions: pain, redness of the skin, and swelling.
    • General side effects: headache, feeling very tired, muscle aches, nausea, fever.
    • Swollen lymph nodes.
    • Blood clots.
    • Unusual feeling in the skin (such as tingling or a crawling feeling) (paresthesia), decreased feeling or sensitivity, especially in the skin (hypoesthesia).
    • Persistent ringing in the ears (tinnitus).
    • Diarrhea, vomiting.

    Severe Allergic Reactions

    There is a remote chance that the Janssen COVID-19 Vaccine could cause a severe allergic reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the Janssen COVID-19 Vaccine. For this reason, your vaccination provider may ask you to stay at the place where you received your vaccine for monitoring after vaccination. Signs of a severe allergic reaction can include:

    • Difficulty breathing
    • Swelling of your face and throat
    • A fast heartbeat
    • A bad rash all over your body
    • Dizziness and weakness

    Blood Clots with Low Levels of Platelets

    Blood clots involving blood vessels in the brain, lungs, abdomen, and legs along with low levels of platelets (blood cells that help your body stop bleeding), have occurred in some people who have received the Janssen COVID-19 Vaccine. In people who developed these blood clots and low levels of platelets, symptoms began approximately one to two-weeks after vaccination. Reporting of these blood clots and low levels of platelets has been highest in females ages 18 through 49 years. The chance of having this occur is remote. You should seek medical attention right away if you have any of the following symptoms after receiving Janssen COVID-19 Vaccine:

    • Shortness of breath,
    • Chest pain,
    • Leg swelling,
    • Persistent abdominal pain,
    • Severe or persistent headaches or blurred vision,
    • Easy bruising or tiny blood spots under the skin beyond the site of the injection.

    These may not be all the possible side effects of the Janssen COVID-19 Vaccine. Serious and unexpected effects may occur. The Janssen COVID-19 Vaccine is still being studied in clinical trials.

    Guillain Barré Syndrome

    Guillain Barré syndrome (a neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis) has occurred in some people who have received the Janssen COVID-19 Vaccine. In most of these people, symptoms began within 42 days following receipt of the Janssen COVID-19 Vaccine. The chance of having this occur is very low. You should seek medical attention right away if you develop any of the following symptoms after receiving the Janssen COVID-19 Vaccine:

    • Weakness or tingling sensations, especially in the legs or arms, that's worsening and spreading to other parts of the body.
    • Difficulty walking.
    • Difficulty with facial movements, including speaking, chewing, or swallowing.
    • Double vision or inability to move eyes.
    • Difficulty with bladder control or bowel function.

    WHAT SHOULD I DO ABOUT SIDE EFFECTS?

    If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital.

    Call the vaccination provider or your healthcare provider if you have any side effects that bother you or do not go away.

    Report vaccine side effects to FDA/CDC Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online to https://vaers.hhs.gov/reportevent.html. Please include "Janssen COVID-19 Vaccine EUA" in the first line of box #18 of the report form.  In addition, you can report side effects to Janssen Biotech Inc. at 1-800-565-4008.

    CAN I RECEIVE THE JANSSEN COVID-19 VACCINE AT THE SAME TIME AS OTHER VACCINES?

    Data have not yet been submitted to FDA on administration of the Janssen COVID-19 Vaccine at the same time as other vaccines. If you are considering receiving the Janssen COVID-19 Vaccine with other vaccines, discuss your options with your healthcare provider.

    Please read Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including full EUA Prescribing Information available at: www.JanssenCOVID19Vaccine.com/EUA-factsheet.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

    About the Janssen Pharmaceutical Companies of Johnson & Johnson

    At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Learn more at www.janssen.com. Follow us at @JanssenGlobal.

    Cautions Concerning Forward-Looking Statements

    This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of a potential preventive vaccine for COVID-19. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies, and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in the company's most recently filed Quarterly Report on Form 10-Q, and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

    (PRNewsfoto/Johnson & Johnson)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/us-cdc-advisory-committee-unanimously-recommends-johnson--johnson-covid-19-vaccine-as-a-booster-for-all-eligible-individuals-who-receive-authorized-covid-19-vaccines-301406308.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
  5. NEW BRUNSWICK, N.J., Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2021 of $1.06 per share on the company's common stock. The dividend is payable on December 7, 2021 to shareholders of record at the close of business on November 23, 2021. The ex-dividend date is November 22, 2021.

    About Johnson & Johnson
    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our…

    NEW BRUNSWICK, N.J., Oct. 21, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2021 of $1.06 per share on the company's common stock. The dividend is payable on December 7, 2021 to shareholders of record at the close of business on November 23, 2021. The ex-dividend date is November 22, 2021.

    About Johnson & Johnson

    At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity.  

    (PRNewsfoto/Johnson & Johnson)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/johnson--johnson-announces-quarterly-dividend-for-fourth-quarter-2021-301406101.html

    SOURCE Johnson & Johnson

    View Full Article Hide Full Article
View All Johnson & Johnson News